Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $276.58M+137% | $319.77M+130% | $297.34M+88.6% | $312.76M+81.1% | $116.59M-6.0% | ||
| $282.25M+134% | $324.65M+128% | $299.95M+85.7% | $316.26M+77.2% | $120.71M-7.6% | ||
| $6.45M-10.9% | $6.74M-10.0% | $6.81M-10.6% | $6.96M-33.8% | $7.24M-32.3% | ||
| $300.35M+117% | $343.32M+114% | $316.55M+75.7% | $333.33M+66.3% | $138.36M-9.6% | ||
| $23.99M+11.2% | $23.75M-14.0% | $21.07M-30.7% | $20.56M-37.7% | $21.57M-38.4% | ||
| —— | —— | $5.49M-53.5% | $5.49M-59.6% | $7.47M-49.2% | ||
| $20.1M-10.9% | $26.55M+1.2% | $28.63M-2.4% | $25.35M-25.8% | $22.56M-41.6% | ||
| $48.96M+15.3% | $50.11M+14.0% | $50.85M+18.3% | $41.05M+8.5% | $42.45M+4.8% | ||
| $88.41M+6.1% | $96.38M+8.5% | $97.57M+6.7% | $84.6M-7.6% | $83.3M-16.0% | ||
| $3K+50.0% | $3K+50.0% | $3K+50.0% | $3K+50.0% | $2K0.0% | ||
| -$753.71M-20.8% | -$711.3M-18.1% | -$683.45M-17.1% | -$650.72M-16.6% | -$623.83M-16.2% | ||
| $211.94M+285% | $246.94M+245% | $218.99M+147% | $248.73M+128% | $55.06M+2.2% | ||
| $300.35M+117% | $343.32M+114% | $316.55M+75.7% | $333.33M+66.3% | $138.36M-9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.